Results 41 to 50 of about 73,540 (330)

Enzymatic Non-Covalent Synthesis of a Versatile Platform for Bioorthogonal Prodrugs Activation to Combat Drug Resistance [PDF]

, 2020
Multidrug resistance (MDR) often leads to the failure of the anticancer treatment. Besides the blockage of those MDR pathways, the development of more potent drugs are of urgent needs but largely postponed due to imbalance between safety and efficacy ...
Qingxin, Yao, Ting, Lin, Chengling, Wu, Yuan, Gao, Shuo, Gao   +4 more
core   +1 more source

Can the Union of Prodrug Therapy and Nanomedicine Lead to Better Cancer Management?

Advanced NanoBiomed Research, 2022
Prodrug‐mediated and nanomedicine‐mediated therapies stand at the forefront of cancer management today. However, a lot of recent research efforts have been focused on identifying novel strategies in treating tumor by combining the techniques and ...
Giredhar Muthiah, Amit Jaiswal
doaj   +1 more source

Ex vivo mass spectrometry-based biodistribution analysis of an antibody-Resiquimod conjugate bearing a protease-cleavable and acid-labile linker

Frontiers in Pharmacology, 2023
Immune-stimulating antibody conjugates (ISACs) equipped with imidazoquinoline (IMD) payloads can stimulate endogenous immune cells to kill cancer cells, ultimately inducing long-lasting anticancer effects.
Lydia Bisbal Lopez, Domenico Ravazza, Matilde Bocci, Aureliano Zana, Lucrezia Principi, Sheila Dakhel Plaza, Andrea Galbiati, Ettore Gilardoni, Jörg Scheuermann, Dario Neri, Dario Neri, Dario Neri, Luca Pignataro, Cesare Gennari, Samuele Cazzamalli, Alberto Dal Corso   +15 more
doaj   +1 more source

Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities [PDF]

, 2020
Prodrugs engineered for preferential activation in diseased versus normal tissues offer immense potential to improve the therapeutic index of preclinical and clinical-stage active pharmaceutical ingredients that either cannot be developed otherwise or ...
Peter, Blume-Jensen, Sattanathan, Paramasivan, Samantha W., Brady, Peyton, Shieh, Farrukh, Vohidov, Olga, Burenkova, Hung V.-T., Nguyen, Jenny, Liu, Paul W., Kopesky, Jennifer, K. Saucier-Sawyer, Michael J., Jessel, Julie, Kim, Sung Jin, Huh, Joelle, Baddour, Donald E., Chickering, Elisa, de Stanchina, Lawrence A., Reiter, Bhavatarini, Vangamudi, David J., Turnquist, Kyriakos D., Economides, Michail V., Shipitsin, Jeremiah, Johnson, James C., Ackley, Nolan M., Gallagher, Matthew R., Golder, Allison M., Neenan, Deborah J. C., Ehrlich, Jannik N., Andersen, William K., Dahlberg, Gaurab, KC   +29 more
core   +3 more sources

Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs

Molecular Therapy: Nucleic Acids, 2013
MGH2.1 is a herpes simplex virus type 1 (HSV1) oncolytic virus that expresses two prodrug-activating transgenes: the cyclophosphamide (CPA)-activating cytochrome P4502B1 (CYP2B1) and the CPT11-activating secreted human intestinal carboxylesterase (shiCE).
Kazue Kasai, Hiroshi Nakashima, Fang Liu, Samantha Kerr, Jiang Wang, Mitch Phelps, Philip M Potter, William B Goins, Soledad A Fernandez, E Antonio Chiocca   +9 more
doaj   +1 more source

Synthesis of 4′-Substituted Carbocyclic Uracil Derivatives and Their Monophosphate Prodrugs as Potential Antiviral Agents

Viruses, 2023
Over the past decades, both 4′-modified nucleoside and carbocyclic nucleoside analogs have been under the spotlight as several compounds from either family showed anti-HIV, HCV, RSV or SARS-CoV-2 activity.
Nicolas G. Biteau, Sarah A. Amichai, Niloufar Azadi, Ramyani De, Jessica Downs-Bowen, Julia C. Lecher, Tamara MacBrayer, Raymond F. Schinazi, Franck Amblard   +8 more
doaj   +1 more source

Organic Carbon Monoxide Prodrugs [PDF]

, 2019
Ongoing efforts towards the development of CO-based therapeutics have resulted in the generation of novel CO prodrugs that release CO via different triggers or stimuli.
Aghoghovbia, Robert
core   +1 more source

The Feasibility of Enzyme Targeted Activation for Amino Acid/Dipeptide Monoester Prodrugs of Floxuridine; Cathepsin D as a Potential Targeted Enzyme

Molecules, 2012
The improvement of therapeutic efficacy for cancer agents has been a big challenge which includes the increase of tumor selectivity and the reduction of adverse effects at non-tumor sites.
Gordon L. Amidon, Yasuhiro Tsume
doaj   +1 more source

Synthesis and Antiviral Activity of a Series of 2′-C-Methyl-4′-thionucleoside Monophosphate Prodrugs

Molecules, 2020
The NS5B RNA-dependent RNA polymerase of the hepatitis C virus (HCV) is a validated target for nucleoside antiviral drug therapy. We endeavored to synthesize and test a series of 4′-thionucleosides with a monophosphate prodrug moiety for their antiviral ...
Zackery W. Dentmon, Thomas M. Kaiser, Dennis C. Liotta   +2 more
doaj   +1 more source

Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine

Molecules, 2017
One of the main obstacles for cancer therapies is to deliver medicines effectively to target sites. Since stroma cells are developed around tumors, chemotherapeutic agents have to go through stroma cells in order to reach tumors.
Yasuhiro Tsume, Adam J. Drelich, David E. Smith, Gordon L. Amidon   +3 more
doaj   +1 more source